减充血剂联合鼻用糖皮质激素治疗慢性鼻炎的疗效与安全性:系统评价与Meta分析
该系统评价与Meta分析纳入6项随机对照试验共1071例慢性鼻炎患者,比较鼻用糖皮质激素联合减充血剂(INCS-D)与单用鼻用糖皮质激素(INCS)的疗效。结果显示两组在鼻部症状总分、鼻塞评分、生活质量问卷及鼻通畅度客观检测上均无显著差异,不良事件发生率亦无差异。提示联合减充血剂并未带来额外获益。
要点
- INCS-D与INCS在鼻部症状总分、鼻塞评分及生活质量上无显著差异。
- 治疗1周后鼻通畅度客观检测(声反射鼻测量、鼻吸气峰流量)两组无差异。
- 不良事件发生率两组相当(风险比1.09,95%CI 0.73-1.62)。
核心结论
- Meta分析未显示在鼻用糖皮质激素基础上加用局部减充血剂对慢性鼻炎有额外获益。
- INCS-D的不良事件发生率与单用INCS相当。
研究设计与样本
- 系统评价与Meta分析,检索MEDLINE和EMBASE数据库。
- 纳入比较INCS-D与单用INCS治疗慢性鼻炎的随机对照试验,共6项研究、1071例患者。
主要发现
- 鼻部症状总分:SMD -0.85(95%CI -2.09至0.40,p=0.18),两组无差异。
- 鼻塞评分:SMD -0.13(95%CI -0.46至0.20,p=0.43),两组无差异。
- 鼻结膜炎生活质量问卷评分:SMD -0.12(95%CI -0.66至0.42,p=0.66),两组无差异。
- 治疗1周后鼻通畅度客观检测:声反射鼻测量SMD 0.04(95%CI -0.68至0.76,p=0.91),鼻吸气峰流量SMD 0.08(95%CI -0.16至0.32,p=0.52),均无差异。
- 不良事件:风险比1.09(95%CI 0.73至1.62),两组无差异。
临床怎么用
- 对于单用鼻用糖皮质激素后鼻塞未改善的慢性鼻炎患者,现有证据不支持常规加用局部减充血剂。
- 联合方案的安全性虽与单药相当,但缺乏疗效优势,临床决策时应权衡利弊。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intranasal corticosteroid (INCS) is the most efficacious medicine for treating chronic rhinitis. A decongestant and INCS combination (INCS-D) is considered for nasal congestion that is not improved by INCS. This study aimed to investigate the effects of INCS-D on chronic rhinitis. METHODS: Literature searches were performed using MEDLINE and EMBASE. Randomized controlled trials studying the effects of INCS-D vs INCS alone for treating chronic rhinitis were included. Data were pooled for meta-analysis. Outcomes were nasal symptoms, disease-specific quality of life, objective tests for nasal patency, and adverse events. RESULTS: Six studies (1071 patients) met the inclusion criteria. There were no differences between INCS-D and INCS on total nasal symptom scores (standardized mean difference [SMD] -0.85; 95% confidence interval [CI], -2.09 to 0.40; p = 0.18), nasal congestion scores (SMD -0.13; 95% CI, -0.46 to 0.20; p = 0.43), and the Rhinoconjunctivitis Quality of Life Questionnaire score (SMD -0.12; 95% CI, -0.66 to 0.42; p = 0.66). After 1 week, there were no differences on objective tests for nasal patency (acoustic rhinometry: SMD 0.04; 95% CI, -0.68 to 0.76, p = 0.91; and peak nasal inspiratory flow: SMD 0.08; 95% CI, -0.16 to 0.32; p = 0.52). Adverse events were not different between INCS-D and INCS (risk ratio 1.09; 95% CI, 0.73 to 1.62). CONCLUSION: Meta-analyses did not show benefits of topical decongestants addition to INCS. Adverse events of INCS-D were comparable with INCS.
引用
- Khattiyawittayakun L, Seresirikachorn K, Chitsuthipakorn W, et al. Effects of decongestant addition to intranasal corticosteroid for chronic rhinitis: a systematic review and meta-analysis. Int Forum Allergy Rhinol. 2018. PMID: 30054985. doi:10.1002/alr.22193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。